13 High Growth Pharma Stocks that are Profitable

Published on February 23, 2023 at 10:50 am by Ramish Cheema in Lists, News

In this piece, we will take a look at 13 high growth pharma stocks that are profitable.

One industry that has rapidly evolved with time and impacted millions, if not billions, of lives is the pharmaceutical sector. Within a hundred years, humanity has managed to cure and prevent diseases that were the cause of death in the pre technological era. One disease that is thought to be mild today but caused widespread loss of life in the early 20th century was syphilis, and data from the Centers for Disease Control (CDC) shows that pneumonia, tuberculosis, and diarrhea consistently ranked among the top four causes of death in the United States between 1900 and 1923 – with millions of people seeing a premature end to their lives.

However, by 1998, only pneumonia ranked in the top ten causes of death in the U.S., and the latest CDC data for 2021 shows that the picture has completely changed as pneumonia is out of the list. This complete shift in the list of causes of death is due to rapid advances made by the pharmaceutical industry, which have reduced deadly diseases of the past to manageable or avoidable illnesses today. This is evidenced by the fact that a Federal Trade Commission (FTC) study that attempted to look into the effects of antibiotics on American health found that between 1946 and 1955, tuberculosis deaths ended up dropping by a stunning 75%.

These days, the pharmaceutical industry has moved forward from simple diseases to leveraging advanced technologies such as gene editing to combat complex illnesses such as cancer. A research report from McKinsey points out the growing role of mRNA technologies in the industry, outlining that these combined with gene and cell therapies have grown from 11% of the total drug development efforts to 21% – in a first for the industry. It adds that this shift in modalities combined with innovational pressure and a loss of power from individual players will be the driving factors for the sector in the future.

Today, we’ll take a look at pharmaceutical companies that are both growing and generating profits. Out of these, the top players are SIGA Technologies, Inc. (NASDAQ:SIGA), Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), and Precigen, Inc. (NASDAQ:PGEN).

Photo by Spencer Davis on Unsplash

Our Methodology

We used a stock tracker to first list down healthcare companies that have a profit margin higher than 25% and an annual quarterly sales growth higher than 20%. These curated companies were then analyzed to determine if they are pharmaceutical firms, such as those that make vaccines, drugs, or therapies, or others such as medical device manufacturers. Then, the constraints were relaxed to firms with a 15% or higher sales growth and the selection process was repeated. Out of all these, the top fifteen were selected and ranked through their sales growth, which was manually calculated to verify the screener’s figures with the latest earnings reports of the firms.

High Growth Pharma Stocks that are Profitable

13. United Therapeutics Corporation (NASDAQ:UTHR)

Q/Q Sales Growth: 16%

Number of Hedge Fund Holders in Q3 2022: 47

United Therapeutics Corporation (NASDAQ:UTHR) is an American biotechnology firm headquartered in Silver Spring, Maryland. The firm manufactures drugs for a variety of complications related to pulmonary hypertension, such as lung and exercise capacity.

United Therapeutics Corporation (NASDAQ:UTHR)’s September quarter of 2022 saw the firm rake in $516 million in revenue, which marked a 16% annual growth. During the same quarter, 47 of the 920 hedge funds polled by Insider Monkey had also held a stake in the company.

United Therapeutics Corporation (NASDAQ:UTHR)’s largest investor is Kurt Von Emster’s VenBio Select Advisor which owns 2.8 million shares that are worth $796 million.

Along with Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), SIGA Technologies, Inc. (NASDAQ:SIGA), and Precigen, Inc. (NASDAQ:PGEN), United Therapeutics Corporation (NASDAQ:UTHR) is a high growth profitable pharma firm.

12. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

Q/Q Sales Growth: 16.4%

Number of Hedge Fund Holders in Q3 2022: 20

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) is a biopharmaceutical company headquartered in New York, New York. The company sells a treatment for biliary cholangitis – a liver disease that damages the bile duct. It is also developing other drugs.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) scored a win in January 2023 when the FDA accepted its new drug application for a liver fibrosis treatment. The firm’s revenue grew by 16.4% during its fiscal quarter that ended in September 2022, and Insider Monkey’s 920 hedge fund survey for the same time period revealed that 20 had bought its shares.

Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)’s largest investor is Srini Akkaraju and Michael Dybbs’s Samsara BioCapital which owns 640,688 shares that are worth $7.9 million.

11. Novo Nordisk A/S (NYSE:NVO)

Q/Q Sales Growth: 27%

Number of Hedge Fund Holders in Q3 2022: 40

Novo Nordisk A/S (NYSE:NVO) is one of the oldest pharmaceutical companies in the world since it was set up in 1923. The firm makes and sells drugs for diabetes, obesity, growth disorders, and other health issues.

Novo Nordisk A/S (NYSE:NVO) reported DKK 48 billion in revenues for its fourth quarter of 2022, which marked a 27% growth over the year ago quarter’s DKK 38.3 billion. Insider Monkey’s Q3 2022 survey of 920 hedge funds revealed that 40 had held a stake in the firm.

Out of these, Jim Simons’ Renaissance Technologies is Novo Nordisk A/S (NYSE:NVO)’s largest investor. It owns 12.6 million shares that are worth $1.7 billion.

10. Avid Bioservices, Inc. (NASDAQ:CDMO)

Q/Q Sales Growth: 32.9%

Number of Hedge Fund Holders in Q3 2022: 15

Avid Bioservices, Inc. (NASDAQ:CDMO) is a contract manufacturing pharmaceutical company that produces drugs and other related products for different firms. These include making antibodies and proteins, alongside other services such as regulatory support. The firm is based in Tustin, California.

Avid Bioservices, Inc. (NASDAQ:CDMO)’s second quarter of its fiscal year 2023, which ended in October last year, saw the firm earn $34.7 million in revenue which marked a 32.9% annual growth. At the same time, the firm also increased its revenue guidance for fiscal 2023 to $150 million from $145 million. 15 of the 920 hedge funds polled by Insider Monkey for last year’s third quarter had invested in the firm.

9. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Q/Q Sales Growth: 45%

Number of Hedge Fund Holders in Q3 2022: 27

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a pharmaceutical firm that focuses on making products for people with neurological problems such as sleep disorders. The firm is headquartered in Plymouth Meeting, Pennsylvania.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) had a bumper third quarter last year when it reported a 45% annual revenue growth that pushed its revenue to $117 million. Insider Monkey scoured through 920 hedge fund holdings for the same time period and found out that 27 had bought its shares.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)’s largest investor is Albert Cha and Frank Kung’s Vivo Capital which owns 2.6 million shares that are worth $143 million.

8. Dynavax Technologies Corporation (NASDAQ:DVAX)

Q/Q Sales Growth: 53%

Number of Hedge Fund Holders in Q3 2022: 22

Dynavax Technologies Corporation (NASDAQ:DVAX) is a biopharmaceutical firm that is headquartered in Emeryville, California. The firm makes and sells hepatitis vaccines.

Dynavax Technologies Corporation (NASDAQ:DVAX)’s fiscal third quarter, which ended in September 2022, saw the firm post $167 million in revenues to mark a 53% annual growth. 22 of the 920 hedge funds part of Insider Monkey’s survey for the same time period had invested in the firm.

Dynavax Technologies Corporation (NASDAQ:DVAX)’s largest investor is Ken Fisher’s Fisher Asset Management which owns 4 million shares that are worth $43 million.

7. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Q/Q Sales Growth: 61%

Number of Hedge Fund Holders in Q3 2022: 18

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) develops and sells treatments for diseases such as muscular atrophy, pressure palsies, and a rare condition in children that harms the signals sent from the nerves to the muscles. It is headquartered in Coral Gables, Florida.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) had a bumper fiscal year in 2022, as the firm posted a whopping 52% revenue growth by bringing in $214 million in revenues. For the fourth quarter, the growth was even stronger, as it stood at 61%. During Q3 2022, 18 of the 920 hedge funds polled by Insider Monkey had invested in the firm.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)’s largest investor is James E. Flynn’s Deerfield Management which owns 5.8 million shares that are worth $109 million.

6. Genmab A/S (NASDAQ:GMAB)

Q/Q Sales Growth: 73.9%

Number of Hedge Fund Holders in Q3 2022: 12

Genmab A/S (NASDAQ:GMAB) is a Danish biotechnology company that develops treatments for cancer, eye diseases, multiple sclerosis, solid tumors, atrophy, celiac disease, and other health problems. The firm was set up in 1999 and is headquartered in Copenhagen, Denmark.

Genmab A/S (NASDAQ:GMAB)’s on a high rolling path. Its third quarter of 2022 revenue saw it bring in DKK 4 billion in sales, marking a 73.9% increase. This growth came after the firm had posted a stunning 68% growth in the previous quarter. Insider Monkey’s Q3 2022 survey of 920 hedge funds revealed that 12 had bought the firm’s shares.

Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital is Genmab A/S (NASDAQ:GMAB)’s largest investor. It owns a $74 million stake that comes via 1.7 million shares.

SIGA Technologies, Inc. (NASDAQ:SIGA), Genmab A/S (NASDAQ:GMAB), Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA), and Precigen, Inc. (NASDAQ:PGEN) are some of the highest growth and profitable pharmaceutical companies.

5. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Q/Q Sales Growth: 80%

Number of Hedge Fund Holders in Q3 2022: 21

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company that develops treatments for lymphoma, immune disorders, cancer, and leukemia. The firm is based in San Diego, California.

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s third quarter of 2022 results saw the firm bring in $209 million in revenue, which marked a strong 80% annual growth. 21 of the 920 hedge funds polled by Insider Monkey during the same time period had also invested in the firm.

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s largest investor in our database is Richard Driehaus’ Driehaus Capital which owns 1.3 million shares that are worth $76 million.

Follow Halozyme Therapeutics Inc. (NASDAQ:HALO)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

4. Vir Biotechnology, Inc. (NASDAQ:VIR)

Q/Q Sales Growth: 263%

Number of Hedge Fund Holders in Q3 2022: 18

Vir Biotechnology, Inc. (NASDAQ:VIR) develops several treatments for diseases such as the coronavirus, hepatitis, HIV, influenza, and other diseases. The firm is based in San Francisco, California.

Vir Biotechnology, Inc. (NASDAQ:VIR) earned $374.6 million in revenue for the three months that ended in September 2022. This enabled the firm to post a whopping 263% annual growth. Insider Monkey’s Q3 2022 survey covering 920 hedge funds revealed that 18 had invested in the company.

Vir Biotechnology, Inc. (NASDAQ:VIR)’s largest investor is Jim Simons’ Renaissance Technologies which owns 1 million shares that are worth $26 million.

Follow Vir Biotechnology Inc. (NASDAQ:VIR)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

3. Precigen, Inc. (NASDAQ:PGEN)

Q/Q Sales Growth: 406%

Number of Hedge Fund Holders in Q3 2022: 17

Precigen, Inc. (NASDAQ:PGEN) is a biotechnology firm that focuses on genetic and cellular therapies. These involve combining genetic components for genetic expression and a gene that improves immune system performance. The firm is headquartered in Germantown, Maryland.

Precigen, Inc. (NASDAQ:PGEN)’s third quarter results saw the firm post $13.4 million in revenue, which, when compared to the year ago quarter’s $3.3 million in sales marked a 406% annual growth. Insider Monkey surveyed 920 hedge funds for the September quarter of 2022 investments to discover that 17 had held a stake in Precigen, Inc. (NASDAQ:PGEN).

Follow Precigen Inc. (NASDAQ:PGEN)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

2. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Q/Q Sales Growth: 725%

Number of Hedge Fund Holders in Q3 2022: 13

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is a biotechnology firm that is developing products for diseases such as cardiovascular problems, arthritis, and skin issues. It is based in Hamilton, Bermuda.

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) is finally on an upward trajectory, as its third quarter of 2022 revenues stood at $92 million, accounting for a 725% annual growth. These revenues were also greater than the firm’s net sales for the first nine months of 2021. 13 of the 920 hedge funds part of Insider Monkey’s Q3 2022 survey of 920 hedge funds had invested in the firm.

Julian Baker and Felix Baker’s Baker Bros. Advisors is Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)’s largest shareholder. It owns 2.7 million shares that are worth $41 million.

Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

1. SIGA Technologies, Inc. (NASDAQ:SIGA)

Q/Q Sales Growth: 1,400%

Number of Hedge Fund Holders in Q3 2022: 15

SIGA Technologies, Inc. (NASDAQ:SIGA) is a pharmaceutical company authorized to sell its products, which include a smallpox treatment, alongside others covering monkeypox and cowpox.

SIGA Technologies, Inc. (NASDAQ:SIGA) had a bumper third quarter of 2022 as its revenues stood at $72 million. When compared to the year ago quarter’s net sales of $4.8 million, this marked a stunning 1,400% annual growth. As of 2022’s third quarter, 15 of the 920 hedge funds polled by Insider Monkey had bought the firm’s shares.

SIGA Technologies, Inc. (NASDAQ:SIGA)’s largest hedge fund shareholder in our database is Touk Sinantha’s AltraVue Capital which owns 1.7 million shares that are worth $12 million.

Follow Siga Technologies Inc (NASDAQ:SIGA)

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

175 Teslas
107 Amazons
140 Metas
84 Googles
65 Microsofts
And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

If you’re thinking about getting in, don’t wait – because once Wall Street catches wind of this story, the easy money will be gone.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Insider Monkey Ads

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returns! Sign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Here’s why this is a deal you can’t afford to pass up:

Access to our Detailed Report on this $3 stock with 400% upside potential.
BONUS REPORT on our #1 AI-Robotics Stock with 10000% upside potential: Our in-depth report dives deep into our #1 AI/robotics stock’s groundbreaking technology and massive growth potential.
One New Issue of Our Premium Readership Newsletter: You will also receive one new issue per month and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.
One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149
Bonus Content: Premium access to members-only fund manager video interviews
Ad-Free Browsing: Enjoy a month of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
Lifetime Price Guarantee: Your renewal rate will always remain the same as long as your subscription is active.
30-Day Money-Back Guarantee: If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Log In

Sign Up

13 High Growth Pharma Stocks that are Profitable

Published on February 23, 2023 at 10:50 am by Ramish Cheema in Lists, News

High Growth Pharma Stocks that are Profitable

13. United Therapeutics Corporation (NASDAQ:UTHR)

12. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

11. Novo Nordisk A/S (NYSE:NVO)

10. Avid Bioservices, Inc. (NASDAQ:CDMO)

9. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

8. Dynavax Technologies Corporation (NASDAQ:DVAX)

7. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

6. Genmab A/S (NASDAQ:GMAB)

5. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Follow Halozyme Therapeutics Inc. (NASDAQ:HALO)

Follow Halozyme Therapeutics Inc. (NASDAQ:HALO)

4. Vir Biotechnology, Inc. (NASDAQ:VIR)

Follow Vir Biotechnology Inc. (NASDAQ:VIR)

Follow Vir Biotechnology Inc. (NASDAQ:VIR)

3. Precigen, Inc. (NASDAQ:PGEN)

Follow Precigen Inc. (NASDAQ:PGEN)

Follow Precigen Inc. (NASDAQ:PGEN)

2. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA)

Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA)

1. SIGA Technologies, Inc. (NASDAQ:SIGA)

Follow Siga Technologies Inc (NASDAQ:SIGA)

Follow Siga Technologies Inc (NASDAQ:SIGA)

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Markets

Insider Trading

Hedge Funds

Retirement

Opinion

Premium

Log In

Sign Up

13 High Growth Pharma Stocks that are Profitable

Published on February 23, 2023 at 10:50 am by Ramish Cheema in Lists, News

Share

High Growth Pharma Stocks that are Profitable

13. United Therapeutics Corporation (NASDAQ:UTHR)

12. Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)

11. Novo Nordisk A/S (NYSE:NVO)

10. Avid Bioservices, Inc. (NASDAQ:CDMO)

9. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

8. Dynavax Technologies Corporation (NASDAQ:DVAX)

7. Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

6. Genmab A/S (NASDAQ:GMAB)

5. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Follow Halozyme Therapeutics Inc. (NASDAQ:HALO)

Follow Halozyme Therapeutics Inc. (NASDAQ:HALO)

4. Vir Biotechnology, Inc. (NASDAQ:VIR)

Follow Vir Biotechnology Inc. (NASDAQ:VIR)

Follow Vir Biotechnology Inc. (NASDAQ:VIR)

3. Precigen, Inc. (NASDAQ:PGEN)

Follow Precigen Inc. (NASDAQ:PGEN)

Follow Precigen Inc. (NASDAQ:PGEN)

2. Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA)

Follow Kiniksa Pharmaceuticals International Plc (NASDAQ:KNSA)

1. SIGA Technologies, Inc. (NASDAQ:SIGA)

Follow Siga Technologies Inc (NASDAQ:SIGA)

Follow Siga Technologies Inc (NASDAQ:SIGA)

Share

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Published on May 16, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up:

Buy This $3 Stock Now Before the 400% Surge Begins

Published on May 15, 2026 at by Inan Dogan, PhD

Here’s why this is a deal you can’t afford to pass up: